Ask Onix
Patent expiry sets stage for generic competition
India's pharmaceutical market is bracing for a seismic shift as the patent on semaglutide-the active ingredient in Novo Nordisk's blockbuster weight-loss drugs Wegovy and Ozempic-expires this Friday. Domestic drugmakers are preparing to flood the market with cheaper generic versions, potentially slashing prices by over 50% and dramatically expanding access to a treatment once limited to affluent patients.
Market potential and industry response
Investment bank Jefferies has labeled the moment a potential "magic-pill moment" for India, forecasting the domestic semaglutide market could reach $1 billion if pricing and adoption align. Analysts predict around 50 branded generics will enter the market within months, mirroring the rapid proliferation seen when the diabetes drug sitagliptin lost patent protection in 2022-when nearly 100 versions emerged within a year.
India's $60 billion pharmaceutical industry, projected to double by 2030, is built on generics. Major players like Cipla, Sun Pharma, Dr Reddy's Laboratories, and Zydus are already gearing up to launch their own versions, with prices expected to drop from the current 8,800-16,000 rupees ($95-$173) per month to as low as 3,000-5,000 rupees ($36-$54).
Health impact and demand drivers
Semaglutide, a GLP-1 receptor agonist, mimics a hormone that regulates appetite and blood sugar, making users feel full sooner and longer. Originally developed for diabetes, it has become a global sensation for weight loss, offering results few other treatments can match. India's anti-obesity drug market has already surged from $16 million in 2021 to nearly $100 million, fueled by rising demand for injectable and oral versions like Rybelsus.
The country faces a dual health crisis: over 77 million people with type-2 diabetes and one of the world's largest populations of overweight adults. Urbanization, sedentary lifestyles, and carbohydrate-heavy diets have exacerbated the problem, creating a vast potential market for affordable weight-loss solutions.
Medical applications and cautionary notes
Beyond endocrinology, GLP-1 drugs are increasingly used by cardiologists to prepare patients for procedures like angioplasty, orthopedic surgeons to reduce joint stress before knee surgery, and pulmonologists to treat obstructive sleep apnea. Mumbai bariatric surgeon Muffazal Lakdawala calls the drugs a "game-changer" but warns: "The quality of generics must be tightly regulated."
Doctors emphasize that these drugs are not a standalone solution. Mumbai diabetologist Rahul Baxi notes that success depends on "right patient selection," including factors beyond BMI, such as diabetes or high cholesterol. Rapid weight loss can lead to muscle loss and frailty, while stopping the drugs often triggers a rebound in appetite. Baxi advocates gradual weight loss, dose escalation, and lifestyle changes for sustainable results.
"If you stop the drugs, the appetite comes back voraciously."
Rahul Baxi, Mumbai diabetologist
Regulatory and ethical challenges
As prices fall, concerns about misuse are growing. Physicians report cases of gym trainers, beauty clinics, and online pharmacies prescribing high doses without proper authority. Mumbai chest physician Bhaumik Kamdar warns, "More access to cheap drugs means a higher chance of abuse."
India's drug regulator recently issued an advisory barring pharmaceutical companies from promoting prescription weight-loss drugs directly to consumers. Advertisements promising dramatic results or downplaying the need for diet and exercise could be deemed misleading, officials stressed, as these medicines should only be used under medical supervision.
Global implications and export potential
India's role as the "pharmacy of the world" could extend to semaglutide generics, with exports potentially scaling to $10 billion in the U.S. alone as obesity rates drive demand. The country already supplies over 200 nations, meeting half of Africa's generic drug needs and 40% of the U.S. market. However, experts caution that maintaining quality standards will be critical to preserving India's reputation.
For now, doctors like Baxi are advising patients to wait: "I am writing on prescriptions: Come to me after 20 March when the prices come down." The coming months will test whether India can balance affordability with oversight, turning a once-exclusive treatment into a widely accessible tool against obesity and diabetes.
